III期黑色素瘤辅助治疗引入后五年生存:全国登记研究
基于瑞典黑色素瘤登记库,纳入2016-2020年诊断的IIIB-D期、<75岁且前哨淋巴结阳性的皮肤黑色素瘤患者,按辅助治疗引入前后分pre组(n=287)和post组(n=349),随访至2024年底。post组72.8%接受辅助治疗(多为PD-1抑制剂),两组5年总生存率分别为67.3%和70.1%,校正后HR 0.96(95%CI 0.73-1.27,P=0.791),未见总生存获益。
要点
- III期黑色素瘤辅助治疗引入后5年总生存无显著改善(校正HR 0.96,P=0.791)。
- post组72.8%接受辅助治疗,以PD-1抑制剂为主,<60岁、男性及原发灶较厚者暴露率更高。
- 各亚组比较均未观察到总生存或黑色素瘤特异性生存差异。
核心结论
- 全国性登记研究显示,III期黑色素瘤引入辅助治疗五年后未观察到总生存获益,提示需审慎评估当前辅助治疗推荐。
研究设计与样本
- 基于瑞典黑色素瘤登记库的全国性、人群登记研究,纳入2016-2020年诊断的IIIB-D期、<75岁且前哨淋巴结阳性的皮肤黑色素瘤患者。
- 按前哨淋巴结活检时间(2018年9月前 vs 自2018年9月起)分为pre组(n=287)和post组(n=349),随访生存至2024年底。
主要发现
- pre组5年总生存率为67.3%(95%CI 62.0-72.9),post组为70.1%(95%CI 65.3-75.2)。
- 校正年龄、性别和肿瘤分期后HR为0.96(95%CI 0.73-1.27),P=0.791。
- post组72.8%接受辅助治疗,多数为PD-1抑制剂,治疗暴露率在<60岁(80.2%)、男性(78.3%)及原发灶较厚者(75.4%)中最高。
- 各亚组比较pre组与post组,未观察到显著的总生存或黑色素瘤特异性生存差异。
临床怎么用
- 对III期黑色素瘤辅助治疗决策应充分权衡生存获益与副作用及成本,结合患者个体情况审慎选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with stage III cutaneous melanoma, adjuvant treatments with PD-1 and BRAF+MEK inhibitors were approved based on improved recurrence-free survival. However, as the treatments have significant side effects and costs, the effect on overall survival remains a matter of great importance. METHODS: Clinical and histopathological parameters were obtained from the Swedish Melanoma Registry for patients diagnosed with stage IIIB-D melanoma in 2016-2020. Patients under the age of 75 years, that had a positive sentinel lymph node (SLN) were included. Patients were divided into two cohorts, depending on if the SLN biopsy was performed before or from September 2018 (pre- and post-cohort), based on the timepoint when adjuvant treatment was introduced. Patients were followed for survival until the end of 2024. RESULTS: The five-year overall survival rates were, 67.3 % (95 % CI 62.0-72.9) in the pre-cohort (n = 287) and 70.1 % (95 % CI 65.3-75.2) in the post-cohort (n = 349), with hazard ratio adjusted for age, sex and tumor stage of 0.96 (95 % CI 0.73-1.27), P=0.791. In the post-cohort 72.8 % received adjuvant treatment, the majority with PD-1 inhibitors where treatment exposure was highest in those < 60 years (80.2 %), males (78.3 %) and those having thicker primary melanomas (75.4 %). No significant overall or melanoma-specific survival differences were observed when comparing the pre- and the post-cohort in different subgroups. CONCLUSIONS: In this nationwide, population and registry-based study there was no overall survival benefit observed five years after the introduction of adjuvant treatment for patients with stage III melanoma. These findings encourage a careful assessment of the current recommendation on adjuvant treatment.
引用
- Helgadottir H, Ny L, Ullenhag GJ, et al. Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study. Eur J Cancer. 2025. PMID: 41500895. doi:10.1016/j.ejca.2025.116201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。